1-6 of 6
Sue Perera
Close
Sort by
Journal Articles

Real-World Treatment Patterns of Patients Initiating Third-Line Therapy in Relapsed or Refractory Multiple Myeloma in Europe

Moritz Lehne, K. Martin Kortuem, Elena Zamagni, Tim d'Estrube, Soham Shukla, Evi Zhuleku, Marco Ghiani, Maya Hanna, Ulf Maywald, Thomas Wilke, Sue Perera
Journal: Blood
Blood (2022) 140 (Supplement 1): 12485–12486.
https://doi.org/10.1182/blood-2022-163586
Published: 2022
Journal Articles

Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment

Rakesh Popat, Sikander Ailawadhi, David Kleinman, Sue Perera, Boris Gorsh, Caitlin Thomas, Sarah Mulnick, Alicia O'Neill, Melissa Ross, Prani Paka, Maya Hanna, Alexa Molinari, Shivaranjani Naine, Heather Gelhorn
Journal: Blood
Blood (2022) 140 (Supplement 1): 7211–7213.
https://doi.org/10.1182/blood-2022-164795
Published: 2022
Journal Articles

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Joshua Richter, Peter Feng Wang, Alexa Molinari, Boris Gorsh, Natalie Boytsov, Suzanne Landi, Sue Perera, Prani Paka, Teresa Palumbo, Mei Sheng Duh, Christopher Yee, Anamika Khanal, Sonia Gupta, Ajai Chari
Journal: Blood
Blood (2022) 140 (Supplement 1): 4338–4340.
https://doi.org/10.1182/blood-2022-164918
Published: 2022
Journal Articles

The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World

Attaya Suvannasankha, Thomas W. LeBlanc, Julia R. Correll, Chloe Carmichael, Boris Gorsh, Mona Martin, Helen Kitchen, Laurie Eliason, Madeleine Thursfield, Natalie Boytsov, Eva Brown Hajdukova, Mary Beth Lewis, Christine Mackay, Prani Paka, Alicia O'Neill, Sue Perera, Shivaranjani Naine, Alexa Molinari, Maya Hanna, David Kleinman
Journal: Blood
Blood (2022) 140 (Supplement 1): 13264–13266.
https://doi.org/10.1182/blood-2022-159637
Published: 2022
Journal Articles

Efficacy and Safety of Third-Line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review

Maya Hanna, Justyna Chorazy, Ike Iheanacho, Boris Gorsh, Peter Feng Wang, Prani Paka, Sue Perera
Journal: Blood
Blood (2022) 140 (Supplement 1): 12559–12560.
https://doi.org/10.1182/blood-2022-167521
Published: 2022
Journal Articles

Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies

Natalie Boytsov, Boris Gorsh, Seth Anderson, Peter Feng Wang, Sue Perera, Meg Franklin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12554–12555.
https://doi.org/10.1182/blood-2022-167184
Published: 2022